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However, polyclonal Treg may cause global immune suppression. 4, 7 In addition, since there are only few antigen-specific Treg in the population of the polyclonal Treg, very large numbers of non-specifically expanded Treg are required to inhibit bone-marrow allograft rejection in animal models. 12 All of these characteristics of polyclonal Treg hamper their clinical applications.
In contrast, adoptive transfer of antigen-specific Treg has been shown to prevent and treat T-cell-mediated inflammatory diseases with high efficiency. In animal models, small number of antigen-specific Treg can suppress experimental autoimmune diseases, 13 prevent GVHD and allograft rejection in bone marrow and solid organ transplantation. 14,15 Importantly, the transfer of antigen-specific Treg prevented target antigen-mediated T-cell responses such as
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5,15-17 Based on these studies, antigenspecific Treg has substantial promise for human immunotherapy.
The reliable induction and expansion of rare antigen-specific Treg is technically challenging. Currently, several protocols for murine antigen-specific Treg induction and expansion have been reported in which either purified CD4 + CD25 -or CD4 + CD25 + cells were co-cultured with autologous dendritic cells (DCs) pulsed with alloantigen in the presence of high-dose IL-2 or directly co-cultured with allogeneic DCs. 14,18-20 Similar protocol has also been reported for generation of human antigen-specific Treg recently. 21 In this protocol,
antigen-specific CD4 + CD25 + Treg can be generated by using the co-culture of CD4 + CD25 -T cells with allogeneic monocyte-derived DCs. However, the large-scale in vitro expansion of alloantigen-specific Treg is difficult because of certain features of DCs. For example, DCs are relatively rare in peripheral blood and are usually derived from apheresis or marrow sources including monocytes. 22, 23 Further, DCs are not homogeneous and include multiple subsets with different functional capacities. 24 Finally, there is no effective way to expand human DCs so far. 25 In addition, the current approaches to generate human DCs in vitro are expensive and laborious. -fold from human peripheral blood mononuclear cells (PBMC). 27 These expanded B cells are effective as APCs and can efficiently induce antigenspecific T cells and cytotoxic T lymphocytes. 26, 27 In this study we developed a novel protocol to induce and expand highly efficient human alloantigen-specific Treg in large-scale by co-culture of naïve CD4 + CD25 -T cells with human allogeneic CD40-activated B cells without any 
Materials and Methods

Generation of CD40-activated B cells
Human peripheral blood was obtained from healthy donors in accordance with the Declaration of Helsinki and ethical committee approval from the Institutional Review Boards of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. PBMC were isolated by density gradient centrifugation as previously reports.
28,29 B cells from PBMC were stimulated via CD40 using NIH3T3 cells transfected with the human CD40 ligand (t-CD40-L cells) as described previously. 27 The transfected cells have been stable for human CD40L
expression over a period of 5 yr, and no other human molecules are expressed on t-CD40-L cells. 27 The lethally irradiated (96Gy) t-CD40-L cells were plated on 6-well plates (Costar, Cambridge, MA) at a concentration of 0.4 × 10 5 cells/well in medium containing 45% DME (Gibco/BRL, Gaithersburg, MD), 45% F12 (Gibco/BRL) 10% FCS, 2 mM glutamine (Gibco/BRL), and 15 µg/ml gentamicin (Gibco/BRL). After an overnight culture at 37°C in 5% CO2, t-CD40L cells were adherent and ready for B-cell culture. PBMC at 2 x 10 6 cells/ml were co-cultured at 37°C in 5% CO 2 with t-CD40L cells in the presence of IL-4 (2 ng/ml; R&D 
Flow cytometry analysis
Cells were phenotypically analyzed using a FACSAria. The following fluorescence-conjugated mAbs were used. Anti-CD4-PE-Cy5, anti-CD45RA-PE, anti-CD45RO-APC were purchased from Caltag Laboratories-Invitrogen (Carlsbad, CA). Anti-CD25-APC, anti-CD62L-APC, anti-CD27-PE, anti-CD44-PE, anti-CCR7-PE, anti-CTLA-4-PE, anti-GITR-PE and their isotypematched control Abs of irrelevant specificity were purchased from BD Biosciences.
Intracellular staining was performed after cell fixation and permeabilization, using Fix and Perm reagents (BD Biosciences) as we reported before. 28, 29, 31 The following mAbs were used:
anti-CTLA-4-PE (BD Biosciences), anti-GITR-PE (BD Biosciences), anti-IL-10-PE (R&D),
anti-TGF-β-PE (IQ-products, Netherlands), and anti-IL-2 (BD Biosciences). For Foxp3 staining, the human Foxp3 staining kit (eBiosciences) was used as we described before.
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Mixed lymphocyte reaction (MLR) assays
The suppressor capacity of T cells induced and expanded in co-culture with allogeneic CD40-activated B cells was studied in an MLR co-culture suppression assay, as we described before with some modifications. 23 
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Blocking studies were performed in the presence of the neutralization mAbs directly against CTLA-4 (10 µg/ml, Ancell, USA), IL-4 (10 µg/ml, R&D), IL-10 (10 µg/ml, eBiosciences), GITR (2 µg/ml, R&D), TGF-β (2 µg/ml, R&D) and their relevant isotype controls.
Statistical analysis
Graphs and statistical analyses were performed with the use of Prism 4.00 for Windows software (GraphPad Software, San Diego, CA). P values of .05 or less were considered significant. Figure 1B ). CD40-activated B cells generated using either sCD40-L or tCD40-L expressed high levels of MHC class I and II molecules and costimulatory molecules CD80 and CD86 at 8 days ( Figure 1C ) and the expression of these molecules remained stable thereafter (data not shown). Figure   3A ). In contrast, CD4 medium cells neither divided nor expressed CD25 and Foxp3 ( Figure 3A ).
Results
CD40
We further examined the suppressive capacity and alloantigen specificity of the Figure 4A ). Most of induced CD4 high Treg lost their CCR7 expression after 6 days of culture, suggesting they had a memory/effector like phenotype and tendency to migrate to inflamed tissues rather than undergo recirculation between the lymph nodes and blood. 38 However, CD4 high Treg still maintained high levels of CD62L expression, which likely would confer effective lymph node homing via high endothelial venules.
We next examined the expression of proteins previously implicated in the suppressive activity of Treg, including cytotoxic T lymphocyte antigen-4 (CTLA-4 or CD152), glucocorticoid-induced TNF receptor (GITR), IL-10 and TGF-β. 39 Figure 4 shows that cell surface CTLA-4 and GITR were clearly detectable by day 3 and gradually increased such that high Treg expressed surface CTLA-4 and GITR, respectively, between day 6 and day 7. This was followed by a gradual decline in surface expression. Total CTLA-4 and GITR expression displayed different kinetics in that they gradually increased from day 3 so that about 60% and 30% of CD4 Similar levels of expression of these molecules could be achieved using hexameric human CD40-ligand, indicating that engagement of CD40 was the essential signal and that other ligands potentially provided by murine fibroblasts were dispensable for B-cell activation. In contrast to prior work 26,27,43 in which autologous CD40-activated B cells were used as APCs in conjunction with IL-2 and IL-7 to generate effector T-cell responses, we found that allogeneic
Treg generation did not require the addition of exogenous cytokines. We speculate that the absence of exogenous cytokines, such as IL-7, and using allogeneic rather than autologous CD40-activated B cells in our system may account for why we observed the differentiation and marked expansion of allogeneic Treg rather than effector T cells in our CD40-activated B cell/naïve CD4 + T-cell co-culture system. Our findings are also consistent with growing evidence that some subsets of B cells exert regulatory activity, and that this may involve in certain contexts an enhancement of Treg activity.
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Using co-culture of allogeneic CD40-activated-B cells with total or naïve CD4 + CD25 -T cells, we generated CD4 high CD25 + Foxp3 + Treg after 5-7 days of culture (Figures 2-3 ).
Importantly, we demonstrated that CD4 high CD25 + Foxp3 + Treg generated from naïve CD4 + CD25 -T-cell precursors were alloantigen-specific (Figure 3 ), whereas those derived from total CD4 + CD25 -T cells which included both naïve and memory cells had no antigen specificity ( Figure 2 ). Treg generated from memory CD4 + CD25 -T cells were also found to have no antigen specificity and could suppress both target and third-party antigen stimulated MLR (data not shown). Consistent with our findings, other groups have also shown that Treg could be generated from both naïve and memory CD4 + T cells after co-culture with allogeneic DCs, and that these two sources of Treg were similarly effective in suppression. 21, 45 However,
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differences in the antigen specificity of these Treg were not investigated in these studies.
21,45
The reasons underlying the marked difference in antigen specificity between the Treg generated (Figure 3 ). This suggests that these cells might potentially be useful for migrating to peripheral lymphoid tissues draining graft sites to suppress T cell-mediated allograft rejection and GVHD. It has previously been demonstrated that ex vivo expanded Treg can retain their regulatory activity and migrate appropriately into the peripheral lymphoid organs in the recipient if they express a high level of CD62L.
12, 47 We also demonstrated that induced alloantigen-specific CD4 In functional analysis, we demonstrated that the alloantigen-specific The mechanisms of Treg suppressive function still remain largely unknown. Evidence from in vitro and in vivo studies in both human and rodents indicate that direct cell-cell contact is required and that some immunoregulatory cytokines may also be involved in the suppression of effector T-cell activity. 39 We also demonstrated that the suppressive functions of For For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 
